DE60320770D1 - Verfahren zur verabreichung von buprenorphin zur behandlung von depression - Google Patents

Verfahren zur verabreichung von buprenorphin zur behandlung von depression

Info

Publication number
DE60320770D1
DE60320770D1 DE60320770T DE60320770T DE60320770D1 DE 60320770 D1 DE60320770 D1 DE 60320770D1 DE 60320770 T DE60320770 T DE 60320770T DE 60320770 T DE60320770 T DE 60320770T DE 60320770 D1 DE60320770 D1 DE 60320770D1
Authority
DE
Germany
Prior art keywords
depression
buprenorphine
administration
treatment
patients suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320770T
Other languages
German (de)
English (en)
Inventor
Robert F Kaiko
Ramiro Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE60320770D1 publication Critical patent/DE60320770D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE60320770T 2002-03-20 2003-03-20 Verfahren zur verabreichung von buprenorphin zur behandlung von depression Expired - Lifetime DE60320770D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20
PCT/US2003/008796 WO2003079945A1 (en) 2002-03-20 2003-03-20 Method of administering buprenorphine to treat depression

Publications (1)

Publication Number Publication Date
DE60320770D1 true DE60320770D1 (de) 2008-06-19

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60320770T Expired - Lifetime DE60320770D1 (de) 2002-03-20 2003-03-20 Verfahren zur verabreichung von buprenorphin zur behandlung von depression

Country Status (12)

Country Link
US (1) US20030181475A1 (cg-RX-API-DMAC7.html)
EP (1) EP1485051B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005528359A (cg-RX-API-DMAC7.html)
AT (1) ATE394097T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003224742A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108217T1 (cg-RX-API-DMAC7.html)
DE (1) DE60320770D1 (cg-RX-API-DMAC7.html)
DK (1) DK1485051T3 (cg-RX-API-DMAC7.html)
ES (1) ES2305457T3 (cg-RX-API-DMAC7.html)
PT (1) PT1485051E (cg-RX-API-DMAC7.html)
SI (1) SI1485051T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003079945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7270830B2 (en) * 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
DE602004009449T2 (de) 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
EP2608670B1 (en) 2010-08-23 2018-10-31 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
US10813925B2 (en) 2011-09-19 2020-10-27 Carmel—Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
SMT201800664T1 (it) * 2011-12-15 2019-01-11 Alkermes Pharma Ireland Ltd Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi
CA2858808C (en) * 2011-12-15 2017-04-18 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
AU637496B2 (en) * 1990-04-24 1993-05-27 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
ATE218328T1 (de) * 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
EP1485051A4 (en) 2006-05-24
SI1485051T1 (sl) 2008-10-31
DK1485051T3 (da) 2008-09-08
US20030181475A1 (en) 2003-09-25
JP2005528359A (ja) 2005-09-22
EP1485051A1 (en) 2004-12-15
ATE394097T1 (de) 2008-05-15
CY1108217T1 (el) 2014-02-12
EP1485051B1 (en) 2008-05-07
PT1485051E (pt) 2008-07-09
ES2305457T3 (es) 2008-11-01
AU2003224742A1 (en) 2003-10-08
WO2003079945A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE310509T1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
EP1795189A3 (en) Method of administering buprenorphine to treat depression
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE60143278D1 (de) Verfahren zur Vorbeugung oder Behandlung von Diabetes
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
Sharaf El-Din et al. Pulsed electromagnetic field (PEMF): Effective adjuvant therapy in venous and vasculitic leg ulcers

Legal Events

Date Code Title Description
8364 No opposition during term of opposition